Trial Profile

A Phase 1/2 Multicenter, Open-label, Dose Escalation, Safety and Efficacy Study of Subretinal Administration of Dual AAV8.MYO7A, AAVB-081 in Subjects With Usher Syndrome Type IB (USH1B) Retinitis Pigmentosa

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 19 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

12 May 2025 According to AAVantgarde Bio media release, updated positive safety results in 8 patients and day 180 results for first subject dosed , presented at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO), held May 4-8, 2025 in Salt Lake City (US).
12 May 2025 Results presented in the AAVantgarde Bio Media Release
10 Mar 2025 According to AAVantgarde Bio media release, the oral presentation from this trial will be presented at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO), to be held May 4-8, 2025 in Salt Lake City (US).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com